Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.
Acta Gastroenterol Belg
; 86(3): 493-494, 2023.
Article
em En
| MEDLINE
| ID: mdl-37814567
ABSTRACT
Reactivation of the hepatitis B virus (HBV) with immunosuppressive status has been well established, mainly due to medications such as immunosuppressive therapy like cytotoxic chemotherapy, rituximab and biologic therapy, immunosuppression after solid and bone-marrow transplantation or long-term corticosteroids therapy. We report here two cases of HBV reactivation due to global hypogammaglobulinemia. Regular HBV serologic screening and PCR for HBV-DNA should be applied for each patient with primary immunosuppressive status and history of chronic HBV infection. The necessity of a preemptive treatment remains debated.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Agamaglobulinemia
/
Hepatite B
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Acta Gastroenterol Belg
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Bélgica